Valneva SE (VIE:VLA)

Austria flag Austria · Delayed Price · Currency is EUR
5.22
+0.31 (6.30%)
At close: Oct 1, 2025
6.30%
Market Cap854.53M
Revenue (ttm)196.33M
Net Income (ttm)-67.04M
Shares Outn/a
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,631
Average Volume13,809
Open5.04
Previous Close4.91
Day's Range5.00 - 5.30
52-Week Range1.75 - 5.26
Beta1.01
RSI64.44
Earnings DateNov 20, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 713
Stock Exchange Vienna Stock Exchange
Ticker Symbol VLA
Full Company Profile

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.

Financial Statements

News

There is no news available yet.